This implies that inhibitors targeting translation initiation regulators are therapeutic candidates in the treatment of aggressive systemic mastocytosis (associated with cKIT D816V) and in AML harbouring the D816V cKIT mutant (present in 10 to 40% of core-binding factor leukaemia [39]). The gene discussed is KIT; the disease is systemic mastocytosis.